Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Celcuity Inc.
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
May 23, 2026
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
May 23, 2026
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
March 18, 2026
←
Previous Page
1
2
3